The effect of thiouracil on the collection of radioactive iodine in experimentally induced thyroid tumors
26
Citation
19
Reference
10
Related Paper
Keywords:
Radioactive iodine
Cite
Citations (0)
Cite
Citations (4)
Article1 July 1952INDICATIONS AND CONTRAINDICATIONS FOR TREATMENT OF THYROID CANCER WITH RADIOACTIVE IODINEWILLIAM H. BEIERWALTES, M.D.WILLIAM H. BEIERWALTES, M.D.Author, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-37-1-23 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptTen years have now elapsed since the first patient with carcinoma of the thyroid was treated with radioactive iodine.1More than 250 thyroid carcinoma patients have been treated since then with radioactive iodine, I131.2Review of the literature and our experience in treating 24 such patients have indicated certain criteria to be of definite value in the selection of patients for I131therapy. Lack of regard for these criteria has, in our hands, led to wasteful use of I131and rise of false hopes in the thyroid cancer patient. It is the purpose of this discussion, therefore, to review these...Bibliography1. FrantzLarsenJaretzki VKWGA: An evaluation of radioactive iodine therapy in metastatic thyroid cancer, J. Clin. Endocrinol. 10: 1084, 1950. CrossrefGoogle Scholar2. Brucer M: Internally administered isotopes for cancer therapy, Nucleonics 10: 47, 1952. Google Scholar3. RawsonMarinelliSkanseTrunnellFluharty RWLDBNJRG: The effect of total thyroidectomy on the function of metastatic thyroid cancer, J. Clin. Endocrinol. 8: 826, 1948. CrossrefGoogle Scholar4. RawsonRallPeacock RWJEW(a) : Limitations and indications in the treatment of cancer of the thyroid with radioactive iodine, J. Clin. Endocrinol. 11: 1128, 1951. (b) Dobyns, B. M., and Maloof, F.: The study and treatment of 119 cases of carcinoma of the thyroid with radioactive iodine, J. Clin. Endocrinol. 11: 1323, 1951. CrossrefGoogle Scholar5. Trunnell JB: The treatment of human thyroid disease with radioactive iodine, Tr. New York Acad. Sc. 11: 195, 1949. CrossrefMedlineGoogle Scholar6. KeatingHainesPowerWilliams FRSFMHMM: Radioiodine-accumulating function of human thyroid gland as diagnostic test in clinical medicine, J. Clin. Endocrinol. 10: 1425, 1950. CrossrefGoogle Scholar7. MeansLerman JHJ: The curves of thyroxine decay in myxedema and of iodine response in thyrotoxicosis: their similarity and its possible significance, Ann. Int. Med. 12: 811, 1938. LinkGoogle Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: Ann Arbor, Michigan*Presented at the Thirty-third Annual Session of the American College of Physicians, Cleveland, Ohio, April 23, 1952.From the Department of Internal Medicine, University of Michigan Medical School. The radioactive iodine used in this investigation was supplied by the Oak Ridge National Laboratories, Oak Ridge, Tennessee, and was obtained under allocation from the United States Atomic Energy Commission. These studies were assisted by a grant from the Michigan Memorial Phoenix Project, University of Michigan. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited bySurgical Management of Well-Differentiated Thyroid Cancer Locally Invasive to the Respiratory TractThe treatment of thyroid carcinoma with radioactive iodineIsotope und SchilddrüseCancer of the ThyroidRadiojod in Diagnostik und Therapie der SchilddrüsenneoplasmenDie malignen SchilddrüsentumorenTherapie der Schilddrüse mit RadiojodKrankheiten der SchilddrüseRADIO‐ACTIVE IODINE (I 131 ) AND PROTEIN‐BOUND IODINE IN THYROID DISORDERS 1 July 1952Volume 37, Issue 1Page: 23-30KeywordsCancer treatmentThyroidThyroid carcinoma Issue Published: 1 July 1952 PDF downloadLoading ...
Radioactive iodine
Cite
Citations (18)
Radioactive iodine
Cite
Citations (7)
Correlation of serum thyroglobulin (Tg) levels with recurrent cancer was performed in 200 patients who had undergone a subtotal thyroidectomy for well-differentiated thyroid carcinoma. Patients were divided into three groups: (1) those not treated postoperatively with radioactive iodine, (2) those treated with low dose (30 mCi) radioactive iodine, and (3) those treated with high dose (50-250 mCi) radioactive iodine. Tg levels proved to be reliable in detecting recurrent thyroid cancer regardless of the dose of radioactive iodine given postoperatively. These results reinforce the recommendation of using the Tg assay as the primary method of following these patients postoperatively, even when there was less than a total thyroidectomy and ablation with radioactive iodine.
Radioactive iodine
Thyroglobulin
Cite
Citations (24)
Radioactive iodine
Ablation Therapy
Radioiodine therapy
Cancer Therapy
Cite
Citations (1)
Radioactive iodine
Thyroglobulin
Cite
Citations (16)
Background: Recently, there has been some controversy regarding the role of radioactive iodine (RAI) ablation in the treatment of low-risk differentiated thyroid carcinoma (DTC), especially papillary thyroid microcarcinoma (PTMC). This study aimed to compare quality of life (QoL) parameters between patients with PTMC who underwent total thyroidectomy (TT) alone and those who underwent TT with RAI ablation. Methods: In this cross-sectional study, patients with PTMC who underwent TT with/without RAI remnant ablation were prospectively enrolled between June 2016 and October 2017. All patients completed three questionnaires: the 12-item short-form health survey (SF-12), thyroid cancer-specific quality of life (THYCA-QoL) questionnaire, and fear of progression (FoP) questionnaire. Results: The TT and TT with RAI groups comprised 107 and 182 patients, respectively. The TT with RAI group had significantly lower serum thyrotropin (TSH) levels than the TT group. However, after matching for TSH levels between the groups (n=100 in both groups), there were no significant differences in baseline characteristics. According to the SF-12, the score for general health was significantly lower in the TT with RAI group than in the TT group (P=0.047). The THYCA-QoL also showed a significant difference in the “felt chilly” score between groups (P=0.023). No significant differences in FoP scores were observed between the groups. Conclusion: Patients with PTMC who underwent TT with RAI ablation experienced more health-related problems than those managed with TT alone. These findings support the idea that RAI ablation should be carefully considered in patients with low-risk DTCs.
Radioactive iodine
Cite
Citations (14)
Radioactive iodine
Radioiodine therapy
Cite
Citations (0)